Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verinurad - AstraZeneca

Drug Profile

Verinurad - AstraZeneca

Alternative Names: RDEA-3170

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ardea Biosciences
  • Developer Ardea Biosciences; AstraZeneca
  • Class Antigouts; Naphthalenes; Propionic acids; Pyridines; Small molecules
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout; Hyperuricaemia; Kidney disorders; Type 2 diabetes mellitus
  • Phase I Renal failure

Most Recent Events

  • 18 Sep 2019 AstraZeneca completes a phase I trial in Renal failure (In volunteers) in Germany (PO, Capsule) (NCT04024501)
  • 20 Jul 2019 Phase-I clinical trials in Renal failure (In volunteers) in Germany (PO, Capsule) (NCT04024501)
  • 17 Jul 2019 AstraZeneca plans a phase I trial for Renal failure in Germany (NCT04024501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top